JAHA:非阻塞性冠状动脉心肌梗死患者预后和死亡率预测因素

2019-07-09 xing.T MedSci原创

由此可见,MINOCA患者和阻塞性冠状动脉疾病心肌梗死患者临床结局相似。肾素-血管紧张素系统阻滞剂和他汀类药物的使用与MINOCA患者的死亡率降低相关。

非阻塞性冠状动脉(MINOCA)心肌梗塞是一种异质性疾病,其预后和死亡率预测仍不明确。近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,该研究旨在比较MINOCA与梗死性冠状动脉疾病心肌梗死之间的预后,并使用全国性、多中心和前瞻性登记中心来确定MINOCA与全因死亡相关的因素。

在入组的13104名连续就诊患者中,选择了未接受过冠状动脉造影的有明显冠状动脉疾病史的患者。主要结果是2年全因死亡。次要结果是心脏死亡、非心脏死亡、再梗塞和重复血运重建。

MINOCA患者(n=396)和梗阻性冠状动脉疾病心肌梗死患者(n=10 871)全因死亡率相似(9.1% vs. 8.8%;风险比[HR]为1.04; 95%CI为0.74 -1.45; P=0.83)。心脏死亡、非心脏死亡和再梗塞的风险在两组之间无显著差异(HR为0.82; 95%CI为0.53-1.28; P=0.38; HR为1.55; 95%CI为0.93-2.56; P=0.09 ; HR为1.23; 95%CI为0.65-2.31; P=0.38)。MINOCA患者重复血运重建发生率较低(1.3% vs. 7.2%; HR为0.17; 95%CI为0.07-0.41; P<0.001)。在多变量回归和倾向得分匹配后,结果是一致的。在一个多变量模型中,研究人员发现了MINOCA患者全因死亡的几个重要预测因子,包括不使用肾素-血管紧张素系统阻滞剂(HR为2.63; 95%CI为1.08-6.25; P=0.033)和他汀类药物(HR为2.17; 95%CI为1.04-4.54; P=0.039)。

由此可见,MINOCA患者和阻塞性冠状动脉疾病心肌梗死患者临床结局相似。肾素-血管紧张素系统阻滞剂和他汀类药物的使用与MINOCA患者的死亡率降低相关。
 
原始出处:

Eun Ho Choo.et al.Prognosis and Predictors of Mortality in Patients Suffering Myocardial Infarction With Non‐Obstructive Coronary Arteries.JAHA.2019.https://www.ahajournals.org/doi/full/10.1161/JAHA.119.011990

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1696892, encodeId=8a5e16968928e, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Oct 05 16:05:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692056, encodeId=a79816920566e, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Nov 07 02:05:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264318, encodeId=e0921264318b7, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Jul 11 09:05:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268178, encodeId=25e712681e864, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Jul 11 09:05:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369364, encodeId=562e36936476, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jul 09 19:05:33 CST 2019, time=2019-07-09, status=1, ipAttribution=)]
    2019-10-05 tomyang96
  2. [GetPortalCommentsPageByObjectIdResponse(id=1696892, encodeId=8a5e16968928e, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Oct 05 16:05:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692056, encodeId=a79816920566e, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Nov 07 02:05:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264318, encodeId=e0921264318b7, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Jul 11 09:05:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268178, encodeId=25e712681e864, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Jul 11 09:05:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369364, encodeId=562e36936476, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jul 09 19:05:33 CST 2019, time=2019-07-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1696892, encodeId=8a5e16968928e, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Oct 05 16:05:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692056, encodeId=a79816920566e, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Nov 07 02:05:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264318, encodeId=e0921264318b7, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Jul 11 09:05:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268178, encodeId=25e712681e864, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Jul 11 09:05:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369364, encodeId=562e36936476, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jul 09 19:05:33 CST 2019, time=2019-07-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1696892, encodeId=8a5e16968928e, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Oct 05 16:05:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692056, encodeId=a79816920566e, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Nov 07 02:05:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264318, encodeId=e0921264318b7, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Jul 11 09:05:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268178, encodeId=25e712681e864, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Jul 11 09:05:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369364, encodeId=562e36936476, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jul 09 19:05:33 CST 2019, time=2019-07-09, status=1, ipAttribution=)]
    2019-07-11 zhaohui6731
  5. [GetPortalCommentsPageByObjectIdResponse(id=1696892, encodeId=8a5e16968928e, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Oct 05 16:05:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692056, encodeId=a79816920566e, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Nov 07 02:05:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264318, encodeId=e0921264318b7, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Jul 11 09:05:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268178, encodeId=25e712681e864, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Jul 11 09:05:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369364, encodeId=562e36936476, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jul 09 19:05:33 CST 2019, time=2019-07-09, status=1, ipAttribution=)]
    2019-07-09 天地飞扬

    学习

    0

相关资讯

Int J Cardiol:非阻塞性冠状动脉心肌梗死患者不良预后的预测因素!

由此可见,预测MINOCA患者新发MACE和死亡的临床因素与之前预测心肌梗死和阻塞性冠状动脉疾病患者心血管事件的因素惊人的相似。

Int J Cardiol:非阻塞性冠状动脉心肌梗死人群水平的发生率和结局分析!

由此可见,MINOCA人群水平的发病率约为5%。尽管他们的解剖发现是良性的,但必须努力改善二级预防策略,以减轻这一人群长期不良后果的负担。

Heart:无阻塞性冠状动脉心肌梗死患者结局分析

由此可见,MINOCA较为常见,其不良结局率约为阻塞性CAD患者的一半。死亡的主要原因是非CVD死亡。MINOCA患者的事件发生率明显高于没有CVD的人群。

Eur Heart J:非阻塞性冠状动脉和阻塞性冠状动脉心肌梗死患者结局比较

由此可见,这项研究证实了接受冠状动脉造影的老年MINOCA患者的预后不良,五分之一的MINOCA患者在12个月内出现了严重的不良事件。